Prostate Cancer, Version 3.2024
Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Rhonda L. Bitting, Brian F. Chapin, Heather H. Cheng, Anthony V. D’Amico, Neil Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xīn Gào, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, R. Jeffrey Karnes, Michael Kuettel, Joshua M. Lang, Tamara L. Lotan, Rana R. McKay, Todd M. Morgan, Julio M. Pow‐Sang, Robert E. Reiter, Mack Roach, Tyler P. Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Russell Z. Szmulewitz, Benjamin A. Teply, Jonathan D. Tward, Richard K. Valicenti, J.K. Wong, Jenna Snedeker, Deborah A. Freedman-Cass
Abstract
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.